In-vitro assessment of cytotoxicity of halloysite nanotubes against HepG2, HCT116 and human peripheral blood lymphocytes

Colloids and Surfaces B: Biointerfaces

Volumn 135, Issue , 2015, Pages 50-55

  Ahmed, Farrukh Rafiq ^a,b   Shoaib, Muhammad Harris ^a   Azhar, Mudassar ^a   Um, Soong Ho ^c   Yousuf, Rabia Ismail ^a   Hashmi, Shahkamal ^d   Dar, Ahsana ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b ZIAUDDIN UNIVERSITY   (Pakistan)

^c Sungkyunkwan University   (South Korea)

^d DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Halloysite nanotubes; HCT116; HepG2; In vitro cytotoxicity; Peripheral blood lymphocytes; Pharmaceutical excipients; Size distribution

Indexed keywords

BLOOD; CLAY; CYTOTOXICITY; KAOLINITE; LYMPHOCYTES; NANOTUBES; SIZE DISTRIBUTION;

HALLOYSITE NANOTUBES; HCT116; HEPG2; IN-VITRO; PERIPHERAL BLOOD LYMPHOCYTES; PHARMACEUTICAL EXCIPIENT;

YARN;

ALUMINUM; EXCIPIENT; HALLOYSITE NANOTUBE; MINERAL; NANOTUBE; SILICATE; UNCLASSIFIED DRUG; ALUMINUM SILICATE; CLAY;

ARTICLE; CLAY; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; HCT116 CELL LINE; HEPG2 CELL LINE; IN VITRO STUDY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; CELL SURVIVAL; DRUG EFFECTS; HUMAN; LYMPHOCYTE; MITOSIS; TUMOR CELL LINE;

ALUMINUM SILICATES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOCYTES; MITOSIS; NANOTUBES; PARTICLE SIZE;

EID: 84938391847     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.07.021     Document Type: Article

References (44)

1. Du M., Guo B., Jia D. Newly emerging applications of halloysite nanotubes: a review. Polym. Int. 2010, 59:574-582.
2. Lvov Y.M., Shchukin D.G., Möhwald H., Price R.R. Halloysite clay nanotubes for controlled release of protective agents. ACS Nano 2008, 2:814-820.
3. Joussein E., Petit S., Churchman J., Theng B., Righi D., Delvaux B. Halloysite clay minerals - a review. Clay Miner. 2005, 40:383-426.
4. Levis S.R., Deasy P.B. Characterisation of halloysite for use as a microtubular drug delivery system. Int. J. Pharm. 2002, 243:125-134.
5. Chi Shi Zhi (Halloysite, Kaolin)-Chinese Herbal Medicine, in: Yin Yang House, 2014.
6. Krejcova K., Deasy P.B., Rabiskova M. Optimization of diclofenac sodium profile from halloysite nanotubules. Ceska Slov. Farm. 2013, 62:71-77.
7. Levis S.R., Deasy P.B. Use of coated microtubular halloysite for the sustained release of diltiazem hydrochloride and propranolol hydrochloride. Int. J. Pharm. 2003, 253:145-157.
8. Forsgren J., Jamstorp E., Bredenberg S., Engqvist H., Stromme M. A ceramic drug delivery vehicle for oral administration of highly potent opioids. J. Pharm. Sci. 2010, 99:219-226.
9. Shi Y.F., Tian Z., Zhang Y., Shen H.B., Jia N.Q. Functionalized halloysite nanotube-based carrier for intracellular delivery of antisense oligonucleotides. Nanoscale Res. Lett. 2011, 6:608.
10. Cornejo-Garrido H., Nieto-Camacho A., Gómez-Vidales V., Ramírez-Apan M.T., del Angel P., Montoya J.A., Domínguez-López M., Kibanova D., Cervini-Silva J. The anti-inflammatory properties of halloysite. Appl. Clay Sci. 2012, 57:10-16.
11. Refusal Details as Recorded in OASIS by FDA for Refusal FS2-1092363-7/1/24, in: Import Refusal Report-US Food and Drug Adminitration, 2009.
12. Vergaro V., Abdullayev E., Lvov Y.M., Zeitoun A., Cingolani R., Rinaldi R., Leporatti S. Cytocompatibility and uptake of halloysite clay nanotubes. Biomacromolecules 2010, 11:820-826.
13. Veerabadran N.G., Price R.R., Lvov Y.M. Clay nanotubes for encapsulation and sustained release of drugs. Nano 2007, 02:115-120.
14. Maisanaba S., Pichardo S., Puerto M., Gutiérrez-Praena D., Cameán A.M., Jos A. Toxicological evaluation of clay minerals and derived nanocomposites: a review. Environ. Res. 2015, 138:233-254.
15. Suh Y.J., Kil D.S., Chung K.S., Abdullayev E., Lvov Y.M., Mongayt D. Natural nanocontainer for the controlled delivery of glycerol as a moisturizing agent. J. Nanosci. Nanotechnol. 2011, 11:661-665.
16. Verma N., Moore E., Blau W., Volkov Y., Ramesh Babu P. Cytotoxicity evaluation of nanoclays in human epithelial cell line A549 using high content screening and real-time impedance analysis. J. Nanopart. Res. 2012, 14:1-11.
17. Fakhrullina G.I., Akhatova F.S., Lvov Y.M., Fakhrullin R.F. Toxicity of halloysite clay nanotubes in vivo: a Caenorhabditis elegans study. Environ. Sci. Nano 2015, 2:54-59.
18. Cervini-Silva J., Nieto-Camacho A., Palacios E., Montoya J.A., Gomez-Vidales V., Ramirez-Apan M.T. Anti-inflammatory and anti-bacterial activity, and cytotoxicty of halloysite surfaces. Colloids Surf. B Biointerfaces 2013, 111C:651-655.
19. Guo M., Wang A., Muhammad F., Qi W., Ren H., Guo Y., Zhu G. Halloysite nanotubes, a multifunctional nanovehicle for anticancer drug delivery. Chin. J. Chem. 2012, 30:2115-2120.
20. Massaro M., Colletti C.G., Noto R., Riela S., Poma P., Guernelli S., Parisi F., Milioto S., Lazzara G. Pharmaceutical properties of supramolecular assembly of co-loaded cardanol/triazole-halloysite systems. Int. J. Pharm. 2015, 478:476-485.
21. Sergent J.A., Paget V., Chevillard S. Toxicity and genotoxicity of nano-SiO2 on human epithelial intestinal HT-29 line cell. Ann. Occup. Hyg. 2012, 56:622-630.
22. Kawata K., Osawa M., Okabe S. In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ. Sci. Technol. 2009, 43:6046-6051.
23. Schleh C., Semmler-Behnke M., Lipka J., Wenk A., Hirn S., Schaffler M., Schmid G., Simon U., Kreyling W.G. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 2012, 6:36-46.
24. Ballarin-Gonzalez B., Dagnaes-Hansen F., Fenton R.A., Gao S., Hein S., Dong M., Kjems J., Howard K.A. Protection and systemic translocation of siRNA following oral administration of chitosan/siRNA nanoparticles. Mol. Ther. Nucleic Acids 2013, 2:e76.
25. Eroglu H.E., Aksoy A., Hamzaoglu E., Budak U., Albayrak S. Cytogenetic effects of nine Helichrysum taxa in human lymphocytes culture. Cytotechnology 2009, 59:65-72.
26. Pyrz W.D., Buttrey D.J. Particle size determination using TEM: a discussion of image acquisition and analysis for the novice microscopist. Langmuir 2008, 24:11350-11360.
27. Bonevich John E., Haller Wolfgang K. Measuring the size of nanoparticles using transmission electron microscopy (TEM). NIST-NCL Joint Assay Protocol, PCC-7 2010, 2-11. National Cancer Institute-Frederick, Nanotechnology Characterization Laboratory.
28. Lialiaris T., Lyratzopoulos E., Papachristou F., Simopoulou M., Mourelatos C., Nikolettos N. Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan. Mutagenesis 2008, 23:347-354.
29. Kim A.R., Ahmed F.R., Jung G.Y., Cho S.-W., Kim D.-I., Um S.H. Hepatocyte cytotoxicity evaluation with zinc oxide nanoparticles. J. Biomed. Nanotechnol. 2013, 9:926-929.
30. Dey S., Das M., Balla V.K. Effect of hydroxyapatite particle size, morphology and crystallinity on proliferation of colon cancer HCT116 cells. Mater. Sci. Eng. C 2014, 39:336-339.
31. Hanif Z., Ahmed F.R., Shin S.W., Kim Y.-K., Um S.H. Size- and dose-dependent toxicity of cellulose nanocrystals (CNC) on human fibroblasts and colon adenocarcinoma. Colloids Surf. B: Biointerfaces 2014, 119:162-165.
32. Surralles J., Carbonell E., Marcos R., Degrassi F., Antoccia A., Tanzarella C. A collaborative study on the improvement of the micronucleus test in cultured human lymphocytes. Mutagenesis 1992, 7:407-410.
33. Alakoc C.E. Halil Erhan, Determining mitotic index in peripheral lymphocytes of welders exposed to metal arc welding fumes. Turkish J. Biol. 2011, 35:325-328.
34. Journeay W.S., Suri S.S., Fenniri H., Singh B. High-aspect ratio nanoparticles in nanotoxicology. Integr. Environ. Assess. Manag. 2008, 4:128-129.
35. Ray P.C., Yu H., Fu P.P. Toxicity and environmental risks of nanomaterials: challenges and future needs. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2009, 27:1-35.
36. Sumantran V.N. Cellular chemosensitivity assays: an overview. Methods Mol. Biol. (Clifton, N.J.) 2011, 731:219-236.
37. Narang A., Desai D. Anticancer drug development. Pharmaceutical Perspectives of Cancer Therapeutics 2009, 49-92. Springer, US. Y. Lu, R.I. Mahato (Eds.).
38. Joseph M.M., Aravind S.R., Varghese S., Mini S., Sreelekha T.T. PST-Gold nanoparticle as an effective anticancer agent with immunomodulatory properties. Colloids Surf. B: Biointerfaces 2013, 104:32-39.
39. United States Pharmacopeia and National Formulary (USP 32-NF 27), in: Uniformity of Dosage Units, United States Pharmacopeia Convention, Rockville, MD, 2011.
40. Tablets Obtained by Direct Compression, in: G. BASF (Ed.) Generic Drug Formulations, BASF, 2005.
41. WHO, Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations, in: P. Development (Ed.), vol. 2014, World Health Organization, Tallin, Estonia, 2007, Workshop.
42. Cellulose, Microcrystalline. Handbook of Pharmaceutical Excipients 2009, 129-132. Pharmaceutical Press and American Pharmaceutical Association, London. R.C. Rowe, P.J. Paul Sheskey, M.E. Quinn (Eds.).
43. Charman Susan A., Charman William N. Oral modified-release delivery systems. Modified-Release Drug Delivery Technology 2003, 1-10. Marcel Dekker, Inc., New York, Basel. M.J. Rathbone, J. Hadgraft, M.S. Roberts (Eds.).
44. Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients, REDBOOK 2000, in: U. FDA (Ed.), US Deparment of Health and Human Services, Silver Spring, MD 2007, pp. 286.